TN-40A
This is a 2-arm, multi-center, open label study to learn if ATG works the same or better than teplizumab in delaying or preventing Stage 3 Type 1 diabetes. Participants will be administered either 2 infusions of ATG or 14 infusions of teplizumab and…
- Investigator
- Michael J Haller
- Status
- Accepting Candidates
- Ages
- 4 Years - 34 Years
- Sexes
- All
EFC18241
This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase 3, 2-arm study for treatment.
The purpose of this study is to measure change in glycemic control and prandial insulin independency over 52 weeks with teplizumab…
- Investigator
- Michael J Haller
- Status
- Accepting Candidates
- Ages
- 1 Year - 25 Years
- Sexes
- All
CIP349
- Investigator
- Michael J Haller
- Status
- Accepting Candidates